Lebrikizumab Gets the Nod in the EU for Atopic Dermatitis Lebrikizumab Gets the Nod in the EU for Atopic Dermatitis

Lebrikizumab, an interleukin-13 inhibitor, is not yet approved in the United States.MDedge News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology News Source Type: news